PUS7 Inhibitors
PUS7 inhibitors encompass a range of chemicals that indirectly affect the functional activity of the protein by targeting various cellular processes and pathways. Staurosporine, for instance, serves as a broad kinase inhibitor, which dampens kinase-dependent signaling pathways, ultimately decreasing the functional activity of PUS7 due to its reliance on phosphorylation events for modulation of its activity. Likewise, LY294002 and U0126 disrupt the PI3K/AKT and MAPK/ERK pathways, respectively, pathways that have a role in regulating protein synthesis and function, including that of PUS7. On the other hand, inhibitors like Cycloheximide, Actinomycin D, Mitomycin C, 5-Fluorouracil, and Puromycin target the fundamental processes of protein synthesis and DNA replication. By inhibiting these processes, these compounds reduce the overall cellular levels of PUS7, thereby decreasing its activity. Cycloheximide and Puromycin, in particular, inhibit translation directly, while Actinomycin D and Mitomycin C affect transcription and DNA replication, leading to reduced PUS7 mRNA and protein levels.
Furthermore, compounds such as Rapamycin target the mTOR pathway, a key regulator of protein synthesis, which can lead to a reduction in PUS7 synthesis. Chloroquine and Brefeldin A influence intracellular trafficking and endosomal processes that could be critical for the proper localization and function of PUS7. MG132, a proteasome inhibitor, generally increases protein levels but can also induce cellularstress that might affect the correct folding and function of PUS7. These chemical inhibitors, therefore, by affecting various biochemical pathways and cellular processes, ensure a comprehensive approach to the functional inhibition of PUS7 without directly interacting with the protein itself. The collective impact of these inhibitors on transcription, translation, post-translational modifications, and intracellular signaling pathways ensures the effective downregulation of PUS7 activity within the cell.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can lead to the downstream inhibition of various signaling pathways. By inhibiting kinase-dependent signaling cascades, Staurosporine indirectly decreases PUS7 activity as PUS7 function is modulated by phosphorylation events. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, thus potentially reducing the overall level of PUS7 through decreased translation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits RNA polymerase and, as a result, blocks transcription in eukaryotic cells. This action would decrease the mRNA levels of PUS7, indirectly reducing its protein level and functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR signaling, a pathway that regulates protein synthesis. By inhibiting mTOR, Rapamycin can indirectly lead to decreased synthesis and activity of PUS7. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C crosslinks DNA, inhibiting DNA replication and transcription. This effect would result in reduced expression of PUS7 due to decreased mRNA synthesis. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, thereby reducing DNA synthesis. This reduction in DNA synthesis can indirectly lead to decreased levels of PUS7. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises endosomal pH, which can affect cellular signaling and trafficking. It might therefore interfere with pathways that are necessary for the correct localization or function of PUS7. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can suppress the AKT signaling pathway, which is involved in regulating various cellular functions including protein synthesis. Inhibiting PI3K/AKT pathway might reduce the activity of proteins whose function is modulated by this pathway, including PUS7. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein trafficking by inhibiting ADP-ribosylation factor (ARF), which might impede the proper localization and functioning of PUS7 within cells. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of proteins. Although it generally increases protein levels, it can lead to cellular stress and potentially impact the correct folding and function of PUS7. | ||||||